XOM +4.4% on crude supply fears; INTC -4.1% on $15B dilution

Monday's session divided cleanly along sector lines: energy and pharma advanced while semiconductors absorbed the weight of Intel's announced $15 billion stock offering. The desk examined 32 tickers; seven posted moves greater than 3%.

Energy leads — $XOM +4.4%

The session's largest gain belonged to $XOM, up 4.4%. The driver was a return of oil supply concerns combined with a strong second-quarter print: ExxonMobil reported $116 billion in Q2 revenue and $14.5 billion in net income, alongside an active share repurchase program. Record Permian Basin production positions XOM as one of the most leveraged U.S. names to any crude price recovery. Brent has ranged widely in 2026 — from the high $130s to the mid-$60s — and tightening international supply gave the Permian barrel renewed bid on Monday.

Space recovery — $SPCX +4.2%

$SPCX, the SpaceX-linked ETF, added 4.2% and closed back above its IPO price. ARK Invest argued Monday that last Wednesday's 14% decline discounted SpaceX's $28.5 trillion total addressable market as outlined in IPO filings. Context: rivals Rocket Lab and AST SpaceMobile both reported mixed second-quarter results, which may have redirected capital toward the primary name in the category.

Semiconductor pressure — $INTC -4.1%, $QCOM -3.4%, $AMAT -3.2%

The session's steepest decliner was $INTC, off 4.1% after the chipmaker announced a $15 billion stock offering to fund AI-focused capacity expansion. Intel shares had nearly tripled in 2026 ahead of Monday, outpacing AMD, Nvidia, and the Philadelphia Semiconductor Index; the dilution announcement unwound a portion of that premium in a single session. $QCOM fell 3.4%. One editorial note worth tracking: the Android growth metric that management once placed at the top of its quarterly summaries now surfaces only when specifically asked — a framing shift the market has not yet fully resolved. $AMAT declined 3.2% ahead of its Q3 earnings report with no discrete intraday catalyst identified.

Pharma — $LLY +3.9%

$LLY gained 3.9% after UK regulators authorized Foundayo, Lilly's oral obesity drug — the company's first European approval and an extension of its GLP-1 portfolio beyond injectables. The clearance is a dateable milestone in a market where manufacturing capacity has become the primary competitive moat between Lilly and Novo Nordisk.

Crypto — $COIN -3.2%

$COIN fell 3.2%. Monday's news flow — CEO Armstrong's public commentary on stablecoin adoption and Marex Group's plan to accept Bitcoin and Ethereum as initial margin collateral — was broadly constructive for the sector. No clean negative catalyst for the move was identified in today's coverage.

Filings desk

No insider transactions above $1 million, material corporate events, or activist stakes cleared the freshness gate today.

What we set aside

One ticker was examined and produced no material news within the window: BRK-B.

The desk is watching Applied Materials' Q3 earnings release for confirmation of whether the AI-driven semiconductor equipment cycle is still accelerating.